Lindbrook Capital’s Inhibrx INBX Stock Holding History

Lindbrook Capital’s Portfolio INBX Stock Details INBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-17	Closed	-$262	–	2861
2024 Q4	$262	Hold	17	–	–	﹤0.01%	2698
2024 Q3	$266	Hold	17	–	–	﹤0.01%	2755
2024 Q2	$241	Buy	+17	New	+$266	﹤0.01%	2691

Other funds holding INBX

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Slotnik Capital Dallas, Texas $342M AUM 105.92% 1-Year Est. Return

Lindbrook Capital's INBX Position: Q1 2025 in Review

Lindbrook Capital sold out of Inhibrx (INBX) in Q1 2025, closing a stake of 17 shares — an estimated $262 sold.

Lindbrook Capital first reported a position in INBX in Q2 2024 and held it in 3 quarters. The position peaked at $266 in Q3 2024. 92 funds tracked by Wall St. Rank hold INBX as of Q1 2025.

Lindbrook Capital reported no remaining Inhibrx position as of Q1 2025 after selling out during the quarter.
Lindbrook Capital sold 17 Inhibrx shares in Q1 2025, an estimated $262.
Lindbrook Capital first reported a position in Inhibrx in Q2 2024 and held it in 3 quarters.
Lindbrook Capital's Inhibrx position peaked at $266 in Q3 2024.
92 funds tracked by Wall St. Rank held Inhibrx as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.